Alzinova: Receives regulatory approval for extension study

Research Note



Redeye leaves a short comment following Alzinova’s announcement of a received approval from regulatory authorities to evaluate a higher dose of the vaccine candidate ALZ-101 in an extension part of the ongoing phase Ib study.


Kevin Sule

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.